A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system in chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy

Trial Profile

A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system in chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Granisetron (Primary) ; Granisetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors ProStrakan
  • Most Recent Events

    • 17 May 2014 Results of a post-hoc analysis in different age groups presented at the 2014 Annual Scientific Meeting of the American Geriatrics Society.
    • 26 Apr 2012 The European Medicines Agency has approved granesitron transdermal patch in Europe based on results from this trial, according to a ProStrakan media release.
    • 01 Oct 2011 Results published in the Supportive Care in Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top